Resolutions adopted at the annual general meeting of Hansa Medical AB (publ)

N.B. the English version below is an office translation. In case of any
discrepancy between the Swedish and the English version, the Swedish version
shall prevail.
The following resolutions, among others, were adopted by the annual general
meeting of Hansa Medical AB (publ) held on 11 May 2016.

Dividend
The annual general meeting resolved that no dividend will be paid for the
financial year 2015.

Discharge from liability
The annual general meeting granted the directors and CEO discharge from
liability in respect of the 2015 financial year.

Board of directors and auditor
The annual general meeting resolved to re-elect Birgit Stattin Norinder, Stina
Gestrelius, Hans Schikan and Per Olof Wallström as Board members and to elect
Ulf Wiinberg and Angelica Loskog as Board members. Ulf Wiinberg was elected
chairman of the Board. The annual general meeting resolved to re-elect KPMG AB
in Malmö as the company’s auditor.

Angelica Loskog, born 1973, is Doctor of Philosophy (Faculty of Medicine) and
adjunct professor at the Department of Immunology, Genetics and Pathology at
Uppsala University. Loskog is scientific advisor to Nexttobe AB, CEO of Lokon
Pharma AB, as well as chairman of Vivolux AB and Repos Pharma AB. She is
independent of the company and its management but not to major shareholders of
Hansa Medical. She owns no shares in the company.

Ulf Wiinberg, born 1958, has extensive experience in the pharmaceutical
industry.  Previously CEO of H. Lundbeck A/S and Wiinberg has held senior
positions at Wyeth. Wiinberg is a Board member of Alfa Laval AB and Nestle
Health and Science and chairman of the Board of Avillion, and is nominated for
the Board of directors of the Belgian pharmaceutical company UCB. He is
independent of the company and its senior management and independent of major
shareholders of Hansa Medical. He owns 75 000 shares in the company.

The annual general meeting resolved on remuneration to the Board as follows.
Remuneration to the Board members: SEK 500,000 to the Chairman of the Board and
SEK 110,000 each to the other Board Members except for Angelica Loskog.
Remuneration to the Board committees: SEK 40,000 to the chairman and SEK 30,000
each to the other Board Members in the audit committee, SEK 40,000 to the
chairman and SEK 25,000 each to the other Board Members in the Remuneration
Committee and SEK 25,000 each to the Board Members in the Scientific Committee.
A Board Member may, if it is in accordance with current tax legislation and
provided that it is cost neutral for the company, be given the possibility to
invoice the remuneration from his own company, provided that the company is
registered for corporate tax (sw. F-skatt). Social contributions fees and VAT
will be added to such remuneration invoiced by Board Member within a business
operation. The annual general meeting furthermore resolved on remuneration to
the auditor according to an authorized account.

In addition, the annual general meeting also adopted resolutions regarding
instructions for the nomination committee as well as guidelines regarding
compensation to senior executives.

The information in this communiqué is disclosed pursuant to the Securities
Markets Act or the Financial Instruments Trading Act. The information was
released for public disclosure on May 12, 2016, at 08.00 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: 46 70-633 30 42
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory
enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical
development, with potential use in transplantation and rare autoimmune diseases.
Additional projects focus on development of new antibody modulating enzymes, as
well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency
departments that is already introduced on the market. The company is based in
Lund, Sweden. Hansa Medical’s share (ticker: HMED) is listed on Nasdaq
Stockholm.